Versartis Trial in Children to Assess Long-Acting Growth Hormone
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1b/2a study of VRS-317 (long-acting growth hormone) in pediatric patients
with growth hormone deficiency. During Phase 1b, pediatric patients each will receive a
single subcutaneous injection of VRS-317. During the Phase 2a stage, patients will receive 6
months of VRS-317 treatment at dose levels selected from the Phase 1b stage. The primary
endpoints for the study are to determine the safety and efficacy of repeat dose VRS-317.